NCT04579757 2025-05-08
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
Phase 1/2 Terminated
Hutchmed
Dana-Farber Cancer Institute
Novartis
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center